Tanke Biosciences Corporation
Tanke Biosciences Corporation
Your view on TNBI
Overview
What the company does, where it operates, and who runs it.
About Tanke Biosciences Corporation
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Vincent W. Renz Jr.
- Headquarters
- East Tower of Hui Hao Building, Las Vegas, CN
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Vincent W. Renz Jr.
- Headquarters
- East Tower of Hui Hao Building, Las Vegas, CN
Tanke Biosciences Corporation, through its subsidiaries, develops, produces, markets, and sells animal nutrition and feed additive products. It operates in four segments: Organic Trace Mineral Additives, Functional Regulation Additives, Herbal Medicinal Additives, and Other.
The company offers organic trace mineral additives under the Qili brand name; feed acidifiers, which are used to prevent microbial degradation of raw materials or finished feeds under the Qilicid name; seasonings; flavor enhancers that are used as the agent in the production of blended feed under the Tankeball name; and herbal medicinal additives blended with feed products under the Extra-Health, Qilimix, and Recoccider names.
It also produces and markets multiple trace mineral premix products for livestock and poultry under the Qilimix name.
In addition, the company provides natural sweeteners and attractants for use with feed for pigs, piglets, fish, and other aquatic animals under the Tankeball name; and water soluble organic multi-vitamin electrolyte, which is fed to animals through dissolving it in drinking water for the animals to consume.
It serves mid-to-large sized feed product factories, large scale feed producers, and farmers. The company sells its products primarily in the People's Republic of China, Southeast Asia, and Latin America. Tanke Biosciences Corporation was founded in 1989 and is headquartered in Guangzhou, the People's Republic of China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tanke Biosciences Corporation, and the rating behind it. TNBI last traded at $0.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tanke Biosciences Corporation. Starting points for Tanke Biosciences Corporation: EPS -$0.0077, beta -0.92 — an Asset Management name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tanke Biosciences Corporation. Tanke Biosciences Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tanke Biosciences Corporation. Trailing twelve-month EPS for Tanke Biosciences Corporation stands at -$0.0077. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tanke Biosciences Corporation. Tanke Biosciences Corporation has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tanke Biosciences Corporation valued side by side against its closest peers. Tanke Biosciences Corporation is measured against Asset Management peers within the Financial Services sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tanke Biosciences Corporation, and how their positions are changing. At a $844,997 market value, institutional positions materially move Tanke Biosciences Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tanke Biosciences Corporation executives and directors. Shares of Tanke Biosciences Corporation have traded between $0.02 and $0.06 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tanke Biosciences Corporation. Tanke Biosciences Corporation is a $844,997 Financial Services company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tanke Biosciences Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tanke Biosciences Corporation. Coverage tracks Tanke Biosciences Corporation within Asset Management (Financial Services). Press releases and market coverage, newest first.